ICON (ICLR) Akcie Kurz
ICON Kurz
Za posledních 19 let vzrostly tržby ICON o 16,5 % ročně a dosáhly 8,25 Mld. USD. Zisk na akcii rostl o 4,4 % ročně za posledních 19 let. U ICON je čistá marže 2,8 % převážně stabilní oproti 2,8 % před několika lety. Konsenzuální 12měsíční cílová cena pro ICON je 175,00 USD, asi nad cenu o 1,0 %. Z 24 analytiků jich 16 doporučuje nákup — celkový konsenzus je Koupit.
Cena akcie ICON
Tato data přes Eulerpool API
100 000 požadavků/měs. zdarma · bez karty
Obchodní model ICON a analýza akcií
Nejčastější otázky týkající se akcie ICON
The main competitors of ICON PLC in the market include other Contract Research Organizations (CROs) such as Covance Inc., QuintilesIMS Holdings Inc., and PAREXEL International Corporation. These companies provide similar services and solutions in the clinical research and development industry, offering competition to ICON PLC's global presence and expertise.
ICON PLC, also known as ICON, is a well-established global provider of clinical research and development services to the pharmaceutical, biotechnology, and medical device industries. Founded in 1990 in Dublin, Ireland, ICON has since expanded its operations worldwide, with offices in over 40 countries. The company offers various services, including clinical trial management, data management and analysis, regulatory support, and post-market surveillance. With a strong focus on innovation and expertise, ICON has successfully collaborated with numerous healthcare organizations to accelerate the development of innovative therapies and improve patient outcomes. Due to its vast experience and industry reputation, ICON PLC continues to be a trusted partner in advancing healthcare solutions globally.
The business model of ICON PLC is centered around providing clinical research services to pharmaceutical, biotechnology, and medical device companies. ICON offers a range of services including clinical trial management, data collection and analysis, regulatory consulting, and patient recruitment. They help their clients with the development and commercialization of new drugs and treatments by conducting clinical trials and ensuring regulatory compliance. With a strong focus on innovation and expertise in the field, ICON PLC has established itself as a trusted partner for the life sciences industry.
ICON PLC is primarily active in the pharmaceutical, biotechnology, and medical device industries.
ICON PLC, a leading clinical research organization, has achieved significant milestones throughout its history. The company's accomplishments include becoming a key player in the development and execution of clinical trials worldwide. ICON PLC has successfully expanded its global footprint, delivering exceptional services in over 100 countries. With a strong focus on innovation and technology, the company has pioneered industry-leading solutions to enhance clinical trial processes and improve patient outcomes. ICON PLC's dedication to excellence has resulted in numerous accolades and recognition within the pharmaceutical and biotechnology industries. By consistently delivering high-quality results and establishing strategic partnerships, ICON PLC has solidified its reputation as a trusted and influential player in the field of clinical research.
ICON PLC is primarily present in various countries and regions globally. With a strong international presence, the company operates in multiple key markets, including the United States, United Kingdom, Ireland, Europe, Asia-Pacific, and the Middle East. This global footprint enables ICON PLC to cater to clients worldwide and deliver its comprehensive range of professional services.
ICON PLC is a leading global provider of clinical research services to pharmaceutical, biotechnology, and medical device industries. ICON PLC is guided by a set of core values and corporate philosophy that focuses on innovation, integrity, collaboration, and excellence. The company's commitment to delivering high-quality research and development solutions, while maintaining ethical practices, has made it a trusted partner for successful clinical trials. With its dedication to advancing healthcare and improving patient outcomes, ICON PLC continues to be a respected and influential player in the industry.
Analytici aktuálně stanovují průměrnou cílovou cenu 170,64 USD pro akcii ICON (medián: 175,00 USD), tedy -1,5 % vůči poslední ceně. Konsensus vychází z 24 hodnocení analytiků.
24 analytiků aktuálně hodnotí akcii ICON: 16 doporučuje koupit, 7 držet a 1 prodat. Pro rok 2026 analytici očekávají u ICON tržby 8,14 Mld. USD a zisk na akcii 11,48 USD.
Při aktuálním kurzu se akcie ICON obchoduje za 154,16 EUR (173,31 USD).
Akcie ICON (ICLR) je kótována na 4 burzách, mimo jiné: NASDAQ (ICLR), Frankfurt (IJF.F), München (IJF.MU), Düsseldorf (IJF.DU).
ICON plc is a leading global company in the field of clinical research and development of pharmaceuticals. It offers a wide range of services in clinical trials, consulting, strategy development, laboratory analysis, and data management. The company is divided into three main business areas: clinical development services, laboratory analysis, and data management. It works closely with its customers and partners to develop groundbreaking medications and treatments. ICON is known for its Enterprise Laboratory Information Management System (LIMS) and EDC solutions. It has a robust business model and is well-positioned for future growth.
Tržby očekávané za ICON činí 8,14 Mld. USD. Tato hodnota je založena na aktuálních finančních údajích a odráží výkonnost společnosti.
Zisk očekávané za ICON činí 878,86 Mil. USD. Čistý zisk odráží ziskovost společnosti po odečtení všech nákladů.
Poměr ceny k zisku (P/E) ICON je aktuálně 15,10. Poměr P/E porovnává aktuální cenu akcie se ziskem na akcii a pomáhá investorům posoudit ocenění akcie ICON.
Poměr ceny k tržbám (P/S) ICON je aktuálně 1,63. Poměr P/S porovnává tržní kapitalizaci s ročními tržbami a slouží jako metrika ocenění akcie ICON.
Score kvality pro ICON je 2/10.
ISIN ICON je IE0005711209. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.
WKN ICON je 932242. WKN (Wertpapierkennnummer) je šestimístný německý identifikační kód cenného papíru.
Ticker ICON je ICLR. Symbol tickeru se používá k obchodování akcií ICON na burze.
ICON akcie
Všechny fundamentální údaje o ICON v podrobné analýze
Naše analýzy akcií společnosti ICON zahrnují důležité finanční ukazatele jako obrat, zisk, P/E poměr, P/S poměr, EBIT, stejně jako informace o dividendách. Dále zkoumáme aspekty jako akcie, tržní kapitalizaci, dluhy, vlastní kapitál a závazky společnosti ICON. Pokud hledáte podrobnější informace o těchto tématech, nabízíme vám na našich podstránkách rozsáhlé analýzy: